Compute Health Acquisition Corp.
CPUH
New York Stock Exchange10.36
USD
-0.22
- -
CIK
0001828608
ISIN
US2048331076
CUSIP
204833107
Return %
Stock
S&P500
1Y
5.39
26.53
3Y
5.61
76.60
5Y
5.61
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Joshua Aaron Fink
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- 1105 North Market Street Wilmington DE United States of America 19890
- IPO Date
- Mar 29, 2021
- CIK
- 0001828608
- Website
- compute-health.com
- Similar Companies
- Business
- Compute Health Acquisition Corp. (NYSE: CPUH) operates as a blank check company, or special purpose acquisition company (SPAC), focused on effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, primarily in the healthcare sector at the intersection of computation and healthcare; it targets opportunities in digital health, medical devices including imaging and robotics, diagnostics, biopharma, telehealth, care delivery, and next-generation payer and provider models. The company, founded in 2020 and headquartered in Wilmington, Delaware, does not conduct significant independent operations or generate revenue prior to completing a business combination. Compute Health maintains a lean structure with minimal employees and relies on its leadership team's expertise from Medtronic, Intel, Digital Surgery, and GE Healthcare to identify and pursue high-growth targets leveraging data access, artificial intelligence, algorithms, and computational power in healthcare. In a major development, Compute Health Acquisition Corp. entered into a definitive business combination agreement with Allurion Technologies in 2023, pursuant to which Allurion, a leader in obesity treatment solutions featuring the swallowable Allurion Gastric Balloon for procedure-less weight loss, became a publicly listed company as Allurion Technologies Holdings, Inc. on the NYSE following the de-SPAC transaction's completion; the deal attracted significant investments from RTW Investments and other strategic backers, supporting Allurion's expansion after treating over 100,000 patients globally and scaling revenue from $20 million in 2020 to $64 million in 2022. Post-merger, CPUH shares reflect ongoing trading activity with a market capitalization around $319 million, low volatility (beta of 0.02), and no dividend yield, indicative of its wind-down phase as a SPAC. The company continues limited operations from its U.S. base, with no further announced acquisitions, partnerships, or strategic shifts in the past 1-2 years.
Allurion Technologies, Inc. and Compute Health Acquisition Corp. Announce Updated Terms to Warrant Agreement Amendment
Allurion, a Global Leader in Weight Loss Technology, to Become Publicly Listed Through Business Combination With Compute Health Acquisition Corp.